- Home
- MPV vs STTK Comparison
MPV vs STTK Comparison
Compare MPV & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- STTK
- Stock Information
- Founded
- MPV 1988
- STTK 2016
- Country
- MPV United States
- STTK United States
- Employees
- MPV N/A
- STTK N/A
- Industry
- MPV Finance Companies
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MPV Finance
- STTK Health Care
- Exchange
- MPV Nasdaq
- STTK Nasdaq
- Market Cap
- MPV 170.6M
- STTK 173.6M
- IPO Year
- MPV N/A
- STTK 2020
- Fundamental
- Price
- MPV $16.64
- STTK $3.73
- Analyst Decision
- MPV
- STTK Strong Buy
- Analyst Count
- MPV 0
- STTK 3
- Target Price
- MPV N/A
- STTK $10.67
- AVG Volume (30 Days)
- MPV 25.2K
- STTK 128.3K
- Earning Date
- MPV 01-01-0001
- STTK 11-07-2024
- Dividend Yield
- MPV 8.71%
- STTK N/A
- EPS Growth
- MPV N/A
- STTK N/A
- EPS
- MPV 1.71
- STTK N/A
- Revenue
- MPV N/A
- STTK $4,123,999.00
- Revenue This Year
- MPV N/A
- STTK $164.45
- Revenue Next Year
- MPV N/A
- STTK N/A
- P/E Ratio
- MPV $9.35
- STTK N/A
- Revenue Growth
- MPV N/A
- STTK 380.09
- 52 Week Low
- MPV $11.18
- STTK $1.33
- 52 Week High
- MPV $16.42
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- MPV 63.91
- STTK 53.41
- Support Level
- MPV $15.88
- STTK $3.63
- Resistance Level
- MPV $16.60
- STTK $3.94
- Average True Range (ATR)
- MPV 0.29
- STTK 0.22
- MACD
- MPV 0.06
- STTK 0.06
- Stochastic Oscillator
- MPV 92.05
- STTK 64.91
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.